BioWorld

Feb. 27, 2003

FDA Approves Guilford's Gliadel As First-Line Therapy For Glioma

The FDA issued Guilford Pharmaceuticals Inc. approval to expand the use of the Gliadel Wafer as a first-line therapy for patients with high-grade malignant glioma. (BioWorld Today) Read More

Buyouts Making As Much Sense As Collaborations In Some Cases

Helicobacter pylori Bacteria Holed Up In The Stomach Is Often A Life Sentence Of Gut Damage, Cancer

Affinium Purchases Preclinical Antibiotic Compounds From GSK

Hollis-Eden Garners $10 Million With Sale Of Convertible Notes

Celltech Joins Bidding War For OGS; Offer Called Inadequate'

Amgen Business Overview Through 2005 Well Received

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 31, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...